GT Biopharma, Inc. GTBP
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based
on our proprietary Tri-specific Killer Engager ("TriKE®"), and Tetra-specific Killer Engager ("Dual Targeting TriKE®")
fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary
therapeutics designed to harness and enhance the cancer killing abilities of a patient's own natural killer cells ("NK cells").
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | — | $0 | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | $0 | $0 |
| R&D | $3.5M | $5.8M | $6.5M | $8.8M | $9.6M | $485.0K | $1.7M | $9.1M | $1.1M | $975.0K |
| SG&A | $8.9M | $8.6M | $7.1M | $12.4M | $47.9M | $6.3M | $9.8M | $12.5M | $134.5M | $8.4M |
| Total operating expenses | — | — | $13.6M | $21.3M | $57.5M | — | $16.1M | $250.1M | $135.6M | $9.4M |
| Operating income | -$12.4M | -$14.4M | -$13.6M | -$21.3M | -$57.5M | -$6.8M | $16.1M | -$250.1M | -$135.6M | -$9.4M |
| Interest expense | $127.0K | — | $213.0K | $8.0K | $718.0K | $3.0M | $2.1M | $9.1M | $8.6M | $6.6M |
| Pre-tax income | — | — | — | — | — | — | -$38.6M | -$259.2M | -$144.2M | $9.8M |
| Income tax | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Net income | -$28.4M | -$13.2M | -$7.6M | -$20.9M | -$58.0M | -$28.3M | -$38.6M | -$259.2M | -$144.2M | $9.8M |
| EPS, basic | -6.68 | -6.94 | -5.64 | -19.66 | -2.06 | — | — | -5.16 | -8.60 | 119.91 |
| EPS, diluted | -6.68 | -6.94 | -5.64 | -19.66 | -2.06 | -6.45 | -0.01 | -5.16 | -8.60 | 119.91 |
| Shares, diluted (wtd. avg.) | $5.5M | $1.9M | $1.3M | $1.1M | $28.2M | $4.4M | $3.4M | $50.2K | $16.8K | $81.5K |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $6.8M | $4.0M | $1.1M | $5.7M | $9.0M | $5.3M | $28.0K | $60.0K | $576.0K | $19.0K |
| Short-term investments | — | — | $12.9M | $10.8M | $23.0M | — | — | — | — | — |
| Total current assets | $8.1M | $4.2M | $14.1M | $16.6M | $32.2M | $5.7M | $274.0K | $90.0K | $576.0K | $21.0K |
| Property, plant and equipment | — | — | — | — | — | — | $0 | $35.0K | $6.0K | $4.0K |
| Total assets | $7.1M | $4.2M | $14.1M | $16.7M | $32.2M | $5.7M | $396.0K | $25.4M | $254.4M | $25.0K |
| Accounts payable | $748.0K | $3.9M | $4.3M | $3.1M | $8.2M | $2.2M | $1.9M | $1.8M | $2.5M | $2.1M |
| Total current liabilities | $2.3M | $5.9M | $6.6M | $4.9M | $10.3M | $35.1M | $19.7M | $14.0M | $2.7M | $18.9M |
| Total liabilities | $31.0M | — | $6.6M | $5.0M | $10.3M | — | $19.7M | $14.0M | $2.7M | $18.9M |
| Retained earnings | -$726.3M | -$695.2M | -$682.1M | -$674.5M | -$653.6M | -$595.8M | -$567.3M | -$528.7M | -$269.5M | -$124.6M |
| Total equity | -$25.9M | -$1.7M | $7.5M | $11.7M | $21.9M | -$29.4M | -$19.3M | $11.4M | $251.7M | -$18.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.9M | -$12.9M | -$8.9M | -$15.2M | -$15.6M | -$7.3M | -$3.7M | -$10.7M | -$5.4M | -$1.9M |
| Depreciation and amortisation | — | — | — | — | — | $0 | $4.0K | $7.0K | $2.0K | $1.0K |
| Stock-based compensation | $432.0K | $230.0K | — | $7.7M | $33.9M | $269.0K | $5.3M | $9.7M | $130.1M | $6.6M |
| Capital expenditure | — | — | — | — | — | — | $0 | $36.0K | $4.0K | $0 |
| Investing cash flow | — | $12.9M | -$2.0M | $12.1M | -$23.0M | $0 | $200.0K | -$36.0K | -$4.0K | $0 |
| Financing cash flow | $15.8M | $3.0M | $6.3M | -$224.0K | $42.3M | $12.5M | $3.4M | $10.2M | $6.0M | $1.9M |
| Dividends paid | $229.0K | — | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-031922.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |